UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 

 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

 
Date of Report (Date of earliest event reported):  January 4, 2016
 

 
COGENTIX MEDICAL, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
000-20970
13-3430173
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
5420 Feltl Road
Minnetonka, Minnesota
 
 
55343
(Address of principal executive offices)
 
(Zip Code)

(952) 426-6140
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

                                                                                                                                                                                        

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
Effective January 4, 2016, the Board of Directors (the “Board”) of Cogentix Medical, Inc. (the “Company”) promoted Darin Hammers to the position of Chief Operating Officer.
 
In connection with Mr. Hammers’ promotion to Chief Operating Officer, Mr. Hammers’ base salary was increased to $300,000, effective January 4, 2016, and his performance bonus award for fiscal 2016 was set at 50% of base salary at target. There were no other changes made to Mr. Hammers’ compensation and benefits or to his employment agreement with the Company.

Mr. Hammers has no family relationships that are required to be disclosed under Item 401(d) of Regulation S-K and is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K. The information required by Items 4.01(b) and (e) of Regulation S-K is hereby incorporated by reference to the Company’s annual report on Form 10-K, as filed with the Securities and Exchange Commission on June 25, 2015.

On January 5, 2016, Brett Reynolds resigned from his position as Senior Vice President and Chief Financial Officer.  His last day with the Company will be January 28, 2016.
 
1

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:  January 8, 2016
COGENTIX MEDICAL, INC.
 
     
   
By:
 
/s/ Brett Reynolds
 
   
Name:
Brett Reynolds
 
   
Title:
Senior Vice President, Chief Financial Officer and Corporate Secretary
 
 
2